Brian Park, PharmD

Drug Information Specialist https://www.cancertherapyadvisor.com

Brian Park, PharmD, is a Drug Information Specialist at MPR. A graduate of the Ernest Mario School of Pharmacy, Rutgers University, Brian worked as a pharmacy manager at Stop & Shop Pharmacy for 8 years. He is a certified diabetes care pharmacist.

All articles by Brian Park, PharmD

Multiple Myeloma

BCMA-Directed CAR T Cell Therapy Gets Priority Review for Multiple Myeloma

Brian Park, PharmD

September 23, 2020

The BLA is supported by data from the open-label, single-arm phase 2 KarMMa study.

Breast Cancer

FDA: Efficacy, Safety Concerns With Breast Cancer Combo Therapy

Brian Park, PharmD

September 11, 2020

Findings showed atezolizumab in combination with paclitaxel did not meet statistical significance for progression free survival and also demonstrated a negative trend in overall survival.

Lung Cancer

Gavreto Approved for Metastatic RET Fusion-Positive NSCLC

Brian Park, PharmD

September 9, 2020

The FDA has approved Gavreto™ (pralsetinib; Blueprint Medicines and Genentech) for the treatment of adults with metastatic RET fusion-positive NSCLC.

Hematologic Cancers

Oral AML Therapy Onureg Gets FDA Approval

Brian Park, PharmD

September 8, 2020

The approval was based on data from the multicenter, randomized, double-blind, placebo-controlled, phase 3 QUAZAR study.

General Oncology

Abbott’s 15-Minute COVID-19 Antigen Test Gets Emergency Use Authorization

Brian Park, PharmD

August 28, 2020

Results are provided within 15 minutes and can be read directly from the testing card.

Lung Cancer

Tepotinib Gets Priority Review for Metastatic NSCLC With METex14 Skipping Mutation

Brian Park, PharmD

August 26, 2020

Tepotinib is an oral MET inhibitor designed to inhibit the oncogenic MET receptor signaling caused by MET (gene) alterations.

Multiple Myeloma

Daratumumab Combo Approved for Relapsed/Refractory Multiple Myeloma

Brian Park, PharmD

August 25, 2020

The approval was based on data from the phase 3 CANDOR study and the phase 1b EQUULEUS trial.

Skin Cancer

FDA: Small Risk of Skin Cancer With Hydrochlorothiazide Use

Brian Park, PharmD

August 24, 2020

Hydrochlorothiazide is indicated for the management of hypertension either as the sole therapeutic agent, or in combination with other antihypertensives.

Uncategorized